~ Buy the JENTADUETO (linagliptin; metformin hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

jentadueto Drug Patent Profile

✉ Email this page to a colleague

When do Jentadueto patents expire, and when can generic versions of Jentadueto launch?

Jentadueto is a drug marketed by Boehringer Ingelheim and is included in two NDAs. There are eleven patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and seventy-three patent family members in forty-five countries.

The generic ingredient in JENTADUETO is linagliptin; metformin hydrochloride. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the linagliptin; metformin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Jentadueto

A generic version of jentadueto was approved as linagliptin; metformin hydrochloride by SUNSHINE on August 30^th, 2021.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for jentadueto?
What are the global sales for jentadueto?
What is Average Wholesale Price for jentadueto?

Summary for jentadueto

International Patents:	373
US Patents:	9
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	3
Clinical Trials:	1
Patent Applications:	34
Drug Prices:	Drug price information for jentadueto
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for jentadueto
What excipients (inactive ingredients) are in jentadueto?	jentadueto excipients list
DailyMed Link:	jentadueto at DailyMed

Drug patent expirations by year for jentadueto

Recent Clinical Trials for jentadueto

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Boehringer Ingelheim	Phase 1

See all jentadueto clinical trials

Pharmacology for jentadueto

Drug Class	Biguanide Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

Paragraph IV (Patent) Challenges for JENTADUETO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JENTADUETO	Tablets	linagliptin; metformin hydrochloride	2.5 mg/500 mg 2.5 mg/850 mg 2.5 mg/1000 mg	201281	8	2015-05-04

US Patents and Regulatory Information for jentadueto

jentadueto is protected by nine US patents and two FDA Regulatory Exclusivities.

Patents protecting jentadueto

DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: LINAGLIPTIN (5 MG DAILY DOSE) AND METFORMIN (WITH OR WITHOUT INSULIN) FOR TREATING TYPE 2 DIABETES PATIENTS WITH RENAL IMPAIRMENT AND INSUFFICIENT GLYCEMIC CONTROL DESPITE PREVIOUS TREATMENT WITH METFORMIN ALONE OR IN COMBINATION WITH INSULIN

8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Uses of DPP-IV inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

FDA Regulatory Exclusivity protecting jentadueto

REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
Exclusivity Expiration: ⤷ Sign Up

PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-002	Jan 30, 2012	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-002	Jan 30, 2012	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for jentadueto

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-002	Jan 30, 2012	⤷ Sign Up	⤷ Sign Up
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-001	Jan 30, 2012	⤷ Sign Up	⤷ Sign Up
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-002	Jan 30, 2012	⤷ Sign Up	⤷ Sign Up
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-003	Jan 30, 2012	⤷ Sign Up	⤷ Sign Up
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-002	Jan 30, 2012	⤷ Sign Up	⤷ Sign Up
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-003	Jan 30, 2012	⤷ Sign Up	⤷ Sign Up
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-001	Jan 30, 2012	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

EU/EMA Drug Approvals for jentadueto

Subscribe to access the full database, or Sign Up
Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Boehringer Ingelheim International GmbH	Jentadueto	linagliptin, metformin hydrochloride	EMEA/H/C/002279 Treatment of adult patients with type-2 diabetes mellitus:Jentadueto is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin.Jentadueto is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.	Authorised	no	no	no	2012-07-19
>Company	>Drugname	>Inn	>Product Number / Indication	>Status	>Generic	>Biosimilar	>Orphan	>Marketing Authorisation	>Marketing Refusal

International Patents for jentadueto

When does loss-of-exclusivity occur for jentadueto?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 1175
Patent: COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DE LA DIPEPTIDIL-PEPTIDASA-4 (DPP4) Y UN FARMACO ACOMPANANTE
Estimated Expiration: ⤷ Sign Up

Australia

Patent: 09232043
Patent: DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Estimated Expiration: ⤷ Sign Up

Brazil

Patent: 0911273
Patent: inibidor de dpp-iv combinado com outro agente antidiabético, comprimidos que compreendem tais formulações, seu uso e processo para sua preparação
Estimated Expiration: ⤷ Sign Up

Canada

Patent: 20450
Patent: NOUVELLES FORMULATIONS, COMPRIMES COMPRENANT DE TELLES FORMULATIONS, LEUR UTILISATION ET LEUR PROCEDE DE PREPARATION (NEW FORMULATIONS, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION)
Estimated Expiration: ⤷ Sign Up

Chile

Patent: 09000809
Patent: Composicion farmaceutica que comprende un inhibidor de la dpp4 1-[(4-metil-quinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-amino-piperidin-1-il)-xantina y metformina o sus sales, junto a l-arginina para estabilizar al inhibidor de dpp4; procedimiento de preparacion de dicha composicion.
Estimated Expiration: ⤷ Sign Up

China

Patent: 1983073
Patent: Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Estimated Expiration: ⤷ Sign Up

Patent: 3083672
Patent: DPP-IV inhibitor combined with further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Estimated Expiration: ⤷ Sign Up

Patent: 6215190
Patent: 与其它抗糖尿病药组合的DPP‑IV抑制剂、包含此类制剂的片剂，和其用途和制备方法 (Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation)
Estimated Expiration: ⤷ Sign Up

Patent: 3648422
Patent: 与其它抗糖尿病药组合的DPP-IV抑制剂、包含此类制剂的片剂，和其用途和制备方法 (DPP-IV inhibitors in combination with other anti-diabetic agents, tablets comprising such formulations, and use and processes for preparation thereof)
Estimated Expiration: ⤷ Sign Up

Colombia

Patent: 51277
Patent: INHIBIDOR DE LA DPP-IV COMBINADO CON MAS DE UN AGENTE ANTIDIABETICO, COMPRIMIDOS QUE COMPRENDEN TALES FORMULACIONES, SU USO Y PROCEDIMIENTOS PARA SU PREPARACIÓN.
Estimated Expiration: ⤷ Sign Up

Denmark

Patent: 85410
Estimated Expiration: ⤷ Sign Up

Ecuador

Patent: 10010489
Patent: Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparación
Estimated Expiration: ⤷ Sign Up

Eurasian Patent Organization

Patent: 9395
Patent: ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ ИНГИБИТОР ДПП-4 И МЕТФОРМИН, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ТВЕРДАЯ ДОЗИРОВАННАЯ ФОРМА, ВКЛЮЧАЮЩАЯ УКАЗАННУЮ КОМПОЗИЦИЮ (PHARMACEUTICAL COMPOSITION COMPRISING A DPP-4 INHIBITOR AND METFORMIN, PROCESS FOR THE PREPARATION THEREOF AND SOLID DOSAGE FORM COMPRISING SAID COMPOSITION)
Estimated Expiration: ⤷ Sign Up

Patent: 8435
Patent: ПРИМЕНЕНИЕ ФАРМАЦЕВТИЧЕСКОЙ КОМПОЗИЦИИ В ВИДЕ ТАБЛЕТКИ С ПЛЕНОЧНЫМ ПОКРЫТИЕМ ДЛЯ ЛЕЧЕНИЯ САХАРНОГО ДИАБЕТА 2 ТИПА (USE OF A PHARMACEUTICAL COMPOSITION IN THE FORM OF A FILM-COATED TABLET IN TREATING TYPE 2 DIABETES MELLITUS)
Estimated Expiration: ⤷ Sign Up

Patent: 1001577
Patent: ИНГИБИТОР ДПП-4 В КОМБИНАЦИИ С ДОПОЛНИТЕЛЬНЫМ ПРОТИВОДИАБЕТИЧЕСКИМ АГЕНТОМ, ТАБЛЕТКИ, ВКЛЮЧАЮЩИЕ УКАЗАННЫЕ КОМПОЗИЦИИ, ИХ ПРИМЕНЕНИЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
Estimated Expiration: ⤷ Sign Up

Patent: 1300121
Patent: ИНГИБИТОР ДПП-4 В КОМБИНАЦИИ С ДОПОЛНИТЕЛЬНЫМ ПРОТИВОДИАБЕТИЧЕСКИМ АГЕНТОМ, ТАБЛЕТКИ, ВКЛЮЧАЮЩИЕ УКАЗАННЫЕ КОМПОЗИЦИИ, ИХ ПРИМЕНЕНИЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
Estimated Expiration: ⤷ Sign Up

European Patent Office

Patent: 85410
Patent: DPP-IV INHIBITEUR COMBINÉ AVEC UN AUTRE AGENT ANTI-DIABÉTIQUE, COMPRIMÉS COMPRENANT LESDITES FORMULATIONS, LEUR UTILISATION ET LEUR PROCÉDÉ DE PRÉPARATION (DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION)
Estimated Expiration: ⤷ Sign Up

Patent: 53403
Patent: INHIBITEUR DPP-IV COMBINÉ À UN AUTRE AGENT ANTIDIABÉTIQUE, COMPRIMÉS COMPRENANT DE TELLES FORMULATIONS, LEUR UTILISATION ET LEUR PROCÉDÉ DE PRÉPARATION (DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION)
Estimated Expiration: ⤷ Sign Up

Patent: 44374
Patent: INHIBITEUR DE DPP-IV COMBINÉ À UN AUTRE AGENT ANTIDIABÉTIQUE, COMPRIMÉS COMPRENANT DE TELLES FORMULATIONS, LEUR UTILISATION ET LEUR PROCÉDÉ DE PRÉPARATION (DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION)
Estimated Expiration: ⤷ Sign Up

Hong Kong

Patent: 49485
Patent: DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION
Estimated Expiration: ⤷ Sign Up

Hungary

Patent: 41649
Estimated Expiration: ⤷ Sign Up

Japan

Patent: 88428
Estimated Expiration: ⤷ Sign Up

Patent: 22068
Estimated Expiration: ⤷ Sign Up

Patent: 11516456
Estimated Expiration: ⤷ Sign Up

Patent: 13237707
Patent: NEW FORMULATION, TABLET COMPRISING THE FORMULATION, THE USE AND PROCESS FOR THE PREPARATION
Estimated Expiration: ⤷ Sign Up

Mexico

Patent: 1232
Patent: INHIBIDOR DE DPP-IV COMBINADO CON OTRO AGENTE ANTIDIABETICO, TABLETAS QUE COMPRENDEN TALES FORMULACIONES, SU USO Y PROCEDIMIENTO PARA SU PREPARACION. (DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION.)
Estimated Expiration: ⤷ Sign Up

Patent: 10010819
Patent: INHIBIDORES DE DPP-IV COMBINADO CON OTRO AGENTE ANTIDIABETICO, TABLETAS QUE COMPRENDEN ESAS FORMULACIONES, SU USO Y PROCEDIMIENTO PARA SU PREPARACION. (DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION.)
Estimated Expiration: ⤷ Sign Up

Morocco

Patent: 200
Patent: صياغات جديدة، وأقراص تتكون من هذه الصيغ، استخدامها وطريقة تحضيرها
Estimated Expiration: ⤷ Sign Up

New Zealand

Patent: 7747
Patent: Combination of 1-[(methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(piperidin-1-yl)-xanthine (BI-1356), metformin and a stabilising agent
Estimated Expiration: ⤷ Sign Up

Patent: 9580
Patent: Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Estimated Expiration: ⤷ Sign Up

Peru

Patent: 091730
Patent: FORMULACIONES QUE COMPRENDEN UN INHIBIDOR DE DPP4
Estimated Expiration: ⤷ Sign Up

Patent: 140960
Patent: FORMULACIONES QUE COMPRENDEN UN INHIBIDOR DE DPP4
Estimated Expiration: ⤷ Sign Up

Poland

Patent: 85410
Estimated Expiration: ⤷ Sign Up

South Africa

Patent: 1005664
Patent: DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION
Estimated Expiration: ⤷ Sign Up

South Korea

Patent: 1611314
Estimated Expiration: ⤷ Sign Up

Patent: 1775942
Estimated Expiration: ⤷ Sign Up

Patent: 110005690
Patent: DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION
Estimated Expiration: ⤷ Sign Up

Patent: 160042174
Patent: 추가의 항당뇨병제와 병용된 ＤＰＰ-ＩＶ 억제제, 이러한 제형을 포함하는 정제, 이들의 용도 및 이들의 제조 방법 (DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION)
Estimated Expiration: ⤷ Sign Up

Patent: 170056021
Patent: 추가의 항당뇨병제와 병용된 ＤＰＰ-ＩＶ 억제제, 이러한 제형을 포함하는 정제, 이들의 용도 및 이들의 제조 방법 (- DPP-IV Inhibitor combined with a further antidiabetic agent tablets comprising such formulations their use and process for their preparation)
Estimated Expiration: ⤷ Sign Up

Spain

Patent: 96124
Estimated Expiration: ⤷ Sign Up

Taiwan

Patent: 27816
Estimated Expiration: ⤷ Sign Up

Patent: 0946534
Patent: New formulations, tablets comprising such formulations, their use and process for their preparation
Estimated Expiration: ⤷ Sign Up

Patent: 1509941
Patent: New formulations, tablets comprising such formulations, their use and process for their preparation
Estimated Expiration: ⤷ Sign Up

Tunisia

Patent: 10000431
Patent: NEW FORMULATIONS, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION
Estimated Expiration: ⤷ Sign Up

Turkey

Patent: 1818886
Estimated Expiration: ⤷ Sign Up

Ukraine

Patent: 4136
Patent: ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ВКЛЮЧАЕТ ИНГИБИТОР ДПП-4 В КОМБИНАЦИИ С ДОПОЛНИТЕЛЬНЫМ ПРОТИВОДИАБЕТИЧЕСКИМ АГЕНТОМ, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ;ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ВКЛЮЧАЄ ІНГІБІТОР ДПП-4 У КОМБІНАЦІЇ З ДОДАТКОВИМ ПРОТИДІАБЕТИЧНИМ АГЕНТОМ, ТА СПОСІБ ЇЇ ОДЕРЖАННЯ (DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION)
Estimated Expiration: ⤷ Sign Up

Uruguay

Patent: 747
Patent: NUEVAS FORMULACIONES, COMPRIMIDOS QUE COMPRENDEN TALES FORMULACIONES, SU USO Y PROCEDIMIENTO PARA SU PREPARACION
Estimated Expiration: ⤷ Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering jentadueto around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Canada	2875706	UTILISATIONS D'INHIBITEURS DE L'ENZYME DPP IV (USE OF DPP IV INHIBITORS)	⤷ Sign Up
Australia	2003253418	8-(3-AMINO-PIPERIDIN-1-YL)-XANTHINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2009121945		⤷ Sign Up
Eurasian Patent Organization	201300213	ПРИМЕНЕНИЕ ИНГИБИТОРОВ DPP IV	⤷ Sign Up
Mexico	2020009911	USOS DE INHIBIORES DE DPP IV. (USES OF DPP-IV INHIBITORS.)	⤷ Sign Up
Ukraine	84275	8-[3-АМИНОПИПЕРИДИН-1-ИЛ]КСАНТИНЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ КАК ЛЕКАРСТВЕННЫХ СРЕДСТВ;8-[3-АМІНОПІПЕРИДИН-1-ІЛ]КСАНТИНИ, СПОСІБ ЇХ ОДЕРЖАННЯ ТА ЇХ ЗАСТОСУВАННЯ ЯК ЛІКАРСЬКИХ ЗАСОБІВ (8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS)	⤷ Sign Up
Spain	2696124		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for jentadueto

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1532149	CR 2011 00030	Denmark	⤷ Sign Up	PRODUCT NAME: LINAGLIPTIN OG SALTE DERAF; NAT. REG. NO/DATE: EU/1/11/707/001-011 20110830; FIRST REG. NO/DATE: EU EU/1/11/707/001-0011 20110830
1084705	C300708	Netherlands	⤷ Sign Up	PRODUCT NAME: LINAGLIPTIN; REGISTRATION NO/DATE: EU/1/11/707/001-011 20111224
0896538	300308	Netherlands	⤷ Sign Up	300308, 20170424, EXPIRES: 20220423
1084705	SPC/GB14/084	United Kingdom	⤷ Sign Up	PRODUCT NAME: LINAGLIPTIN; REGISTERED: UK EU/1/11/707/001-011 20110830
1532149	PA2011013,C1532149	Lithuania	⤷ Sign Up	PRODUCT NAME: LINAGLIPTINUM; REGISTRATION NO/DATE: EU/1/11/707/001, 2011-08-24 EU/1/11/707/002, 2011-08-24 EU/1/11/707/003, 2011-08-24 EU/1/11/707/004, 2011-08-24 EU/1/11/707/005, 2011-08-24 EU/1/11/707/006, 2011-08-24 EU/1/11/707/007, 2011-08-24 EU/1/11/707/008, 2011-08-24 EU/1/11/707/00 2011082
0896538	CA 2007 00030	Denmark	⤷ Sign Up
1084705	CA 2014 00062	Denmark	⤷ Sign Up	PRODUCT NAME: SAXAGLIPTIN OG FARMACEUTISK SALTE DERAF, HERUNDER SAXAGLIPTIN HYDROCHLORID; REG. NO/DATE: EU/1/09/545/001-015 20091001
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description